MITOSOL Drug Patent Profile

Which patents cover Mitosol, and what generic alternatives are available?

Mitosol is a drug marketed by Glaukos and is included in one NDA. There are five patents protecting this drug.

This drug has nine patent family members in five countries.

The generic ingredient in MITOSOL is mitomycin. There are seven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the mitomycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mitosol

A generic version of MITOSOL was approved as mitomycin by HIKMA on April 19^th, 1995.

Summary for MITOSOL

International Patents:	9
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	72
Clinical Trials:	12
Patent Applications:	4,931
What excipients (inactive ingredients) are in MITOSOL?	MITOSOL excipients list
DailyMed Link:	MITOSOL at DailyMed

Recent Clinical Trials for MITOSOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 2
ECOG-ACRIN Cancer Research Group	Phase 2
Mayo Clinic	Phase 2

See all MITOSOL clinical trials

US Patents and Regulatory Information for MITOSOL

MITOSOL is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes			Y
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes			Y	Y
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes			Y
Glaukos	MITOSOL	mitomycin	FOR SOLUTION;TOPICAL	022572-001	Feb 7, 2012		RX	Yes	Yes			Y

International Patents for MITOSOL

See the table below for patents covering MITOSOL around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2007272514	Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
Canada	2659314	DISPOSITIF ET PROCEDE DE RECONSTITUTION D'UN PRODUIT PHARMACEUTIQUE ET PREPARATION DU PRODUIT PHARMACEUTIQUE EN VUE D'UNE APPLICATION TRANSITOIRE (APPARATUS AND METHOD FOR RECONSTITUTING A PHARMACEUTICAL ANDPREPARING THE RECONSTITUTED PHARMACEUTICAL FOR TRANSIENT APPLICATION)
European Patent Office	2046653	DISPOSITIF ET PROCÉDÉ DE RECONSTITUTION D'UN PRODUIT PHARMACEUTIQUE ET PRÉPARATION DU PRODUIT PHARMACEUTIQUE EN VUE D'UNE APPLICATION TRANSITOIRE (APPARATUS AND METHOD FOR RECONSTITUTING A PHARMACEUTICAL AND PREPARING THE RECONSTITUTED PHARMACEUTICAL FOR TRANSIENT APPLICATION)
European Patent Office	3175843	APPAREIL ET PROCÉDÉ POUR RECONSTITUER UN PRODUIT PHARMACEUTIQUE ET PRÉPARER LE PRODUIT PHARMACEUTIQUE RECONSTITUÉ POUR UNE APPLICATION TRANSITOIRE (APPARATUS AND METHOD FOR RECONSTITUTING A PHARMACEUTICAL AND PREPARING THE RECONSTITUTED PHARMACEUTICAL FOR TRANSIENT APPLICATION)
Japan	2009543608
Japan	2014097399	一時的な適用のために薬剤を再構成し再構成した薬剤を調合するための器具及び方法 (APPARATUS AND METHOD FOR RECONSTITUTING PHARMACEUTICAL AND PREPARING RECONSTITUTED PHARMACEUTICAL FOR TRANSIENT APPLICATION)

Mitosol Market Dynamics and Financial Trajectory (FY timeline, pricing, launch-to-growth drivers, and IP/regulatory headwinds)

Last updated: June 10, 2026

Mitosol’s market trajectory depends on the product’s U.S. regulatory status, channel reimbursement position, and the strength and timing of its Orange Book patent estate. Without the active ingredient, dosage form (topical/oral/injectable), NDA/BLA identifier, and the relevant FDA labeling, a complete, accurate market and financial build-out cannot be produced.

What is Mitosol’s active ingredient, dosage form, and FDA regulatory status?

Featured snippet: A market dynamics and financial trajectory assessment requires Mitosol’s FDA product identifier (NDA/BLA) and labeling attributes (strength, dosage form, route) that determine coverage, payer placement, and exclusivity timelines.

Which U.S. application does “Mitosol” map to?

• NDA or ANDA number determines Orange Book listings and Paragraph IV risk.
• BLA determines whether biosimilar competition applies.

What are the labeled indications that drive demand?

• Indication mix drives prescription volume, patient starts, and payer utilization management.
• Coverage status differs sharply by therapeutic area.

How fast does Mitosol grow after launch, and what drives adoption?

Featured snippet: Growth rate is mostly explained by payer coverage, formulary placement, prescriber access, and competitive substitution risk.

Launch-and-adoption drivers to model

• Formulary status (commercial and Medicare Part D star impacts for many retail-led products).
• Prior authorization or step therapy requirements.
• Wholesale inventory and channel fill timing (launch-quarter sell-through versus sell-in).
• Differentiation versus incumbent standards of care.

Market dynamics that change the growth curve

• Entry of generics or authorized generics (price compression).
• Off-label substitution where allowed by reimbursement policies.
• Practice pattern changes based on guideline updates.

When does Mitosol lose exclusivity, and how does that map to revenue compression?

Featured snippet: Exclusivity expiry timing is the single most important determinant of forecast revenue volatility for small-molecule drug products.

Exclusivity buckets that matter for financial trajectory

• U.S. patent exclusivity (Orange Book)
• Patent term (primary patents and formulation/method-of-use patents)
• Any pediatric exclusivity adjustment
• Regulatory exclusivity (if applicable to the product’s approval pathway)

How to translate expiration timing into finance

• Revenue compression typically begins after the first at-risk launch event.
• Settlement-driven “no-launch” periods can shift the compression date by quarters.

What patents protect Mitosol, and how strong is the patent estate?

Featured snippet: Patent strength is measured by coverage of the exact marketed formulation and the earliest enforceable claims with realistic remaining term.

Patent categories to inventory from the Orange Book

• Drug substance patents (core active ingredient)
• Drug product/formulation patents (excipients, crystal forms, stability, delivery system)
• Method-of-use patents (indications, dosing regimens)
• Manufacturing/process patents (scale-up, purification, polymorph control)

Which jurisdictions matter for competition

• U.S. controls Paragraph IV risk and FDA listing outcomes.
• EU and other jurisdictions matter for parallel trade and multinational pricing, but U.S. is the key constraint for generic launch.

What generic entry risks exist for Mitosol, including Paragraph IV filings?

Featured snippet: The existence and count of Orange Book-listed patents tied to Mitosol governs the number of potential Paragraph IV triggers and the likely settlement structure.

What to look for in litigation signals

• Whether any ANDA challengers filed Paragraph IV certifications.
• Whether the cases have moved to Markman, trial, or appellate posture.
• Whether any settlements include “launch date carveouts” or “design-around” mechanisms.

How settlement terms typically affect financial trajectory

• “No-AG” and “no-customer” provisions can slow erosion.
• Allowed-to-launch dates can create stepwise revenue drops rather than continuous decay.

What is the Orange Book status of Mitosol?

Featured snippet: Orange Book status determines whether generic substitution is legally blocked and which patents are enforceable at the point of any new competitor entry.

Orange Book checklist for a revenue forecast model

• Listed patents (numbers, expiration dates, patent type)
• Use code mappings (drug product and indication scope)
• Withdrawal or expiration status updates
• Whether multiple patents block the same intended use

What formulations or delivery variants are protected for Mitosol?

Featured snippet: Formulation-specific patents can extend revenue even after method-of-use exclusivity ends.

Common formulation IP that delays substitution

• Extended-release or modified-release design
• Particle size distribution or polymorph/crystal form
• Preservative system or stability/packaging constraints
• Bioavailability-enhancing excipients

Delivery-system competition risks

• Competing products with different release profiles may avoid direct substitution.
• If generics must match release characteristics tightly, launch timing and cost increase.

What patent litigation affects Mitosol, and what is the current posture?

Featured snippet: Litigation posture is a near-term predictor of either settlement-driven delay or court-ordered launch permission.

Typical litigation milestones that change expectations

• Filing of first complaints and amended complaints
• Claim construction (Markman) outcomes
• Summary judgment rulings and injunctive relief
• Settlement agreement announcements

How does Mitosol compare with alternative therapies on market access and pricing pressure?

Featured snippet: Competitive dynamics depend on whether Mitosol is category-leading, second-line, or interchangeable with multiple standards.

Competitive landscape dimensions

• Therapeutic class substitutes (same mechanism, same indication)
• Non-cross-hatched formularies and payer restrictions
• Site-of-care differences (inpatient versus outpatient)

What drives price elasticity

• Whether guidelines require Mitosol specifically.
• Whether payer coverage is “preferred” or “restricted.”
• Patient out-of-pocket thresholds in retail channels.

Commercial performance: what matters in the financial trajectory model?

Featured snippet: Financial trajectory should be modeled from volume, net price realization, and channel dynamics, not gross sales alone.

Core KPIs to track by quarter

• Prescriptions or equivalents (TRx or units)
• Net sales and net price realization (list less rebates/discounts)
• Channel inventory and sell-in versus sell-through
• Gross-to-net bridge: rebates, chargebacks, copay assistance, returns
• Customer concentration (top wholesalers, pharmacy chains, PBMs)

Revenue inflection points

• Formulary wins/losses and payer contract renewals
• Competitive launches that shift utilization
• Supply disruptions or manufacturing constraints affecting fill rates

Which companies are likely to challenge or commercialize substitutes for Mitosol?

Featured snippet: Generic challengers typically come from ANDA filers already active in the same therapeutic category and formulation style.

Competitor archetypes

• Established generic manufacturers targeting high-liquidity dosage forms
• Specialty generics focusing on niche formulations or restricted-use indications
• Authorized generics through settlement structures

Licensing and commercialization patterns

• Co-promotion or distribution agreements that alter net price
• Manufacturing and supply agreements that constrain substitution speed

Key timeline framework for Mitosol revenue under exclusivity and generic entry

Featured snippet: A timeline forecast aligns exclusivity, patent expiry, litigation milestones, and FDA approvals into a single expected compression window.

Timeline elements to anchor

• First commercial sale date
• Major labeling and indication expansions
• Earliest relevant Orange Book patent expiration
• Any pediatric exclusivity adjustments
• Any settlement “no-launch” expiration date
• Expected generic launch window if unblocked

How to interpret uncertainty without losing model discipline

• Use probability-weighted scenarios based on litigation posture and patent expiry sequencing.
• Separate “legal entry risk” (FDA approval) from “commercial entry” (distribution and contracting).

Key Takeaways

• A credible market and financial trajectory for Mitosol requires the exact FDA product mapping (NDA/BLA), dosage form, and labeling, because exclusivity, Orange Book listings, and litigation drive revenue compression and generic entry.
• Revenue forecasts should be built from volume adoption, net price realization, and rebate dynamics, with inflection points aligned to Orange Book patent expirations and any Paragraph IV or settlement events.
• Patent estate composition (drug substance, formulation, method-of-use) determines whether erosion starts at the earliest expiration date or is delayed by formulation/indication-specific barriers.

FAQs

1. Does Mitosol face biosimilar competition, or only generic small-molecule competition?
2. Which Orange Book patents typically block generic substitution for Mitosol’s specific dosage form?
3. How do Paragraph IV filings and settlement agreements change the expected timing of Mitosol net sales decline?
4. What payer coverage factors most affect Mitosol prescribing and TRx growth?
5. How should a model separate legal approval versus actual commercial launch for Mitosol competitors?

References

1. FDA Orange Book (access via Drugs@FDA and Orange Book search).
2. FDA Drugs@FDA database.